



FAX FORM AND CLINICAL DOCUMENTATION

STIMULANTS AND RELATED AGENTS - ANALEPTICS (e.g., PROVIGIL / NUVIGIL / SUNOSI / WAKIX)

PRIOR AUTHORIZATION FORM (form effective 1/6/2025)

Prior authorization guidelines for **Stimulants and Related Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at https://www.pa.gov/en/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.html.

Diagnosis (submit documentation): Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)? Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.	☐New request ☐Renewal request	# of pages:	- Flesciber name.				
LTC facility contact/phone: Beneficiary name: City/state/zip: Beneficiary ID#: DOB: Phone: Fax: CLINICAL INFORMATION Drug requested: Directions: Quantity: Refills Diagnosis (submit documentation): Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)? Complete all sections that apply and submit documentation for each item.	Name of office contact:	Specialty:					
Beneficiary name: City/state/zip: Beneficiary ID#: DOB: Phone: Fax: CLINICAL INFORMATION Drug requested: Directions: Quantity: Refills: Diagnosis (submit documentation): Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)? Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.	Contact's phone number:	NPI:		State license #:			
Beneficiary ID#: DOB:	LTC facility contact/phone:	Street address:					
CLINICAL INFORMATION Drug requested: Directions: Quantity: Refills: Diagnosis (submit documentation): Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)? Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.	Beneficiary name:	City/state/zip:					
Drug requested: Directions: Quantity: Refills Diagnosis (submit documentation): Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)? Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.	Beneficiary ID#:	DOB:	Phone:		Fax:		
Directions: Diagnosis (submit documentation): Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)? Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.	CLINICAL INFORMATION						
Diagnosis (submit documentation): Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)? Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.	Drug requested:			Strength:			
Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)? Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.	Directions:			Quantity:		Refills:	
Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.	Diagnosis (submit documentation):			DX code (required):			
Check all that apply and submit documentation for each item.	Will the beneficiary receive concurrent treatment with a sedative/hypnotic medication(s)?						
	· · · · · · · · · · · · · · · · · · ·						
INITIAL requests							
 For treatment of narcolepsy: Diagnosis is consistent with current International Classification of Sleep Disorders criteria (e.g., MSLT, overnight PSG, hypocaton 1 concentration, clinical assessment, etc.) 							
 For treatment of shift work sleep disorder: Diagnosis is consistent with current International Classification of Sleep Disorders criteria (e.g., shift work schedule, sleep log actigraphy monitoring, other causes ruled out, clinical assessment, etc.) 							
3. For treatment of obstructive sleep apnea/hypopnea syndrome: Diagnosis is consistent with current International Classification of Sleep Disorders criteria (e.g., overnight PSG, out-of-center testing, associated medical or psychiatric disorders, clinical assessment, etc.) Tried and failed continuous positive airway pressure (CPAP) while adherent to treatment to resolve daytime sleepiness demonstrated by: Epworth Sleepiness Scale >10 Multiple sleep latency test (MSLT) <8 minutes							



HEALTH PARTNERS PLANS Phone 215-991-4300 Fax 1-866-240-3712

FAX FORM AND CLINICAL DOCUMENTATION

	Cannot use CPAP – reason:				
	Tried and failed an oral appliance for OSAHS to resolve daytime sleepiness				
4.	For treatment of fatigue related to multiple sclerosis: Is currently receiving treatment for MS Is not receiving treatment for MS – reason:				
5.	For a NON-PREFERRED <u>analeptic</u> Stimulants and Related Agent: Has a history of trial and failure of or a contraindication or an intolerance to the preferred <u>analeptic</u> Stimulants and Related Agents that are approved or medically accepted for treatment of the beneficiary's diagnosis (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.)				
RENEWAL requests					
1.	For all requests: Experienced a positive clinical response to the requested analeptic				
2.	2. For a NON-PREFERRED <u>analeptic</u> Stimulants and Related Agent: Has a history of trial and failure of or a contraindication or an intolerance to the preferred <u>analeptic</u> Stimulants and Related Agents that are approved or medically accepted for treatment of the beneficiary's diagnosis (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.)				
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO 866-240-3712					
Pre	scriber Signature: Date:				

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.